DOC

Urine Detection

DOC (4-chloro-2,5-dimethoxyamphetamine) is an amphetamine-derived psychedelic with a long duration of action and corresponding extended detection window. Due to its structural relationship to amphetamine, DOC and its metabolites may trigger presumptive positive results on standard amphetamine immunoassays. Urine detection windows are estimated at 2 to 4 days following ingestion when analyzed by immunoassay, and potentially longer with LC-MS/MS methods. The extended duration of action (up to 20 hours or more) means the body is eliminating parent compound and metabolites over a prolonged period.

Blood and Serum Detection

Blood detection windows for DOC are approximately 12 to 36 hours after oral ingestion, reflecting the compound's long pharmacological half-life. Peak plasma concentrations occur 2 to 4 hours post-ingestion. The slow offset of effects correlates with sustained measurable blood concentrations. LC-MS/MS provides the most sensitive and specific blood analysis.

Standard Drug Panel Inclusion

DOC is NOT specifically listed on standard 5-panel, 10-panel, or 12-panel drug screens. However, unlike most psychedelics, DOx-series amphetamines may cross-react with amphetamine immunoassays due to their intact amphetamine backbone. A presumptive positive for amphetamine on initial screening is a realistic possibility. On confirmatory testing by GC-MS or LC-MS/MS, the result would not confirm as amphetamine or methamphetamine, and would be reported as negative unless the laboratory specifically includes DOx compounds in their confirmatory panel. Most routine clinical laboratories do not test for DOx amphetamines.

Confirmatory Methods

Definitive identification of DOC requires GC-MS or LC-MS/MS with reference standards specific to DOx compounds. The amphetamine backbone makes GC-MS analysis straightforward without derivatization in most cases. Some forensic toxicology laboratories include DOx amphetamines in extended novel psychoactive substance panels. The relatively long detection window compared to other psychedelics provides a larger sampling window for confirmatory testing.

Reagent Testing (Harm Reduction)

The Marquis reagent produces variable color reactions with DOx amphetamines, ranging from orange-brown to olive-green depending on the specific compound. The Mecke reagent may produce blue-green to brown reactions. The Mandelin reagent typically shows green to brown. Critically, the Ehrlich reagent shows NO reaction with DOx amphetamines, which distinguishes them from lysergamides and tryptamines. Because DOx compounds are sometimes sold on blotter paper mimicking LSD, the Ehrlich test is an essential safety tool: absence of a purple reaction on blotter strongly suggests the substance is not LSD and may be a DOx compound or NBOMe. Given the very long duration of DOx compounds (12-24+ hours), correct identification prior to ingestion is important for safety planning.

Identify the Substance

If sourced on blotter paper, use an Ehrlich reagent to exclude LSD contamination (Ehrlich is negative for DOx, which are not indoles). Positive identification of DOC requires Mecke (blue-green) or Hofmann reagent. Purchasing from tested research chemical vendors with analytical documentation is strongly preferred.

Dose Guidelines

• Threshold: 0.5–1 mg |Common: 1–2.5 mg |Strong: 2.5–4 mg
• Use a milligram-accurate scale or volumetric liquid dosing — visual dose estimation at this scale is unacceptable
• Wait 3–4 hours before any adjustment. The slow onset is the primary cause of accidental overdose

Full-Day-Plus Planning

DOC requires a completely clear day and the following day as well. Allocate 30–36 hours of protected time. Have a trip sitter available or on call. Do not drive or operate machinery for at least 24 hours post-ingestion. Inform someone of your situation.

Managing the Stimulant Component

• Eat a nutritious meal 2–4 hours before dosing; food will become unappealing for most of the experience
• Have electrolyte drinks and snacks available for later in the experience
• Limit caffeine completely before and during — compounded stimulant effects are unpleasant and increase cardiovascular risk
• Magnesium glycinate before dosing reduces jaw tension

Recognizing Vasoconstriction

Symptoms requiring medical attention: cold, white, painful, or numb extremities — particularly fingers and toes. This represents peripheral ischemia and may require vasodilator treatment. Emergency personnel should be told the substance involved.

Extreme Duration Risk

The 18–30 hour duration of DOC means that all the risks of psychedelic use — bad psychological experiences, behavioral impairment, cardiovascular stimulation — are sustained for an unusually prolonged period. The inability to sleep during the experience, combined with the stimulant burden, produces significant physical exhaustion.

Vasoconstriction

DOC, like all DOx compounds, produces significant peripheral vasoconstriction. Severe cases present as cold, pale extremities with pain, and have been documented to require medical vasodilator treatment in high-dose scenarios. This represents a rare but serious physical toxicity not seen with indole psychedelics.

Cardiovascular Strain

Amphetamine-type cardiovascular stimulation sustained for 18–30 hours is the defining physical safety concern. Elevated heart rate and blood pressure over this duration represent substantial risk in individuals with cardiovascular risk factors.

Psychological Risks

The extended duration transforms any difficult psychological experience into an unusually prolonged ordeal. At higher doses, DOC can produce psychosis-like states with paranoia, thought disorder, and dissociation. These states, combined with the stimulant drive of the amphetamine scaffold, may produce agitated, unpredictable behavior.

Drug Interactions

• MAOIs — severely potentiated toxicity; absolute contraindication
• Lithium — unpredictable CNS effects, seizure risk
• Stimulants — compounded cardiovascular strain over the multi-hour experience
• Cannabis — frequently intensifies and disinhibits already strong effects unpredictably

Regulatory Status

United States

DOC (2,5-dimethoxy-4-chloroamphetamine) was placed into Schedule I of the Controlled Substances Act by the DEA effectiveJanuary 16, 2024, through a final rule published in the Federal Register (88 FR 86290, December 13, 2023). The scheduling covers DOC including its salts, isomers, and salts of isomers . Prior to this explicit scheduling, DOC was prosecutable under theFederal Analogue Act as a structural and pharmacological analogue of DOB and DOM (both Schedule I).

International Control

DOC's parent compounds DOM (2,5-dimethoxy-4-methylamphetamine) andDOB (2,5-dimethoxy-4-bromoamphetamine) are listed inSchedule I of the 1971 UN Convention on Psychotropic Substances. DOC itself was added to UN scheduling through action by theCommission on Narcotic Drugs, reflecting growing international concern about substituted amphetamine psychedelics .

Other Jurisdictions

• United Kingdom: Controlled as aClass A substance under the Misuse of Drugs Act 1971, captured under the generic definition for ring-substituted amphetamines.
• Germany: Scheduled underAnlage I of the Betaubungsmittelgesetz (BtMG), with penalties up to five years imprisonment for unauthorized possession, production, or distribution.
• Canada: Controlled under the Controlled Drugs and Substances Act as an amphetamine analogue.
• Australia: Listed in Schedule 9 of the Poisons Standard.

References

DEA. Schedules of Controlled Substances: Placement of 2,5-Dimethoxy-4-iodoamphetamine (DOI) and 2,5-Dimethoxy-4-chloroamphetamine (DOC) in Schedule I. 88 FR 86290. UNODC. Substance Details: DOC. Early Warning Advisory on New Psychoactive Substances.